secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001437749-25-014618
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex licenses exclusive patent rights to Reqorsa for glioblastoma from UTHealth Houston
--------------------------------------------------------------------------------

- Exclusive patent license with UTHealth Houston grants Genprex commercial rights to Reqorsa for GBM.
- Previous positive preclinical data (Oct 2024) showed Reqorsa reduced GBM cell viability and suppressed migration.
- TUSC2 tumor suppressor identified as novel target for glioblastoma by UTHealth Houston researchers.
- Company believes results support further in vivo evaluation in malignant glioma mouse models.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925014618/0001437749-25-014618-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925014618/gnpx20250428_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-014618

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer